This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schaefer, G. Articles by Akita, R. W. Search for Related Content PubMed PubMed Citation Articles by Schaefer, G. Articles by Akita, R. W.

Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression

Department of Translational Oncology, Genentech, Inc., South San Francisco, California

Requests for reprints: Gabriele Schaefer, Department of Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-6431; Fax: 650-225-1411; E-mail: schaefer{at}gene.com.

Erlotinib (Tarceva), is an orally available, reversible inhibitor of epidermal growth factor receptor (EGFR; HER1) that exhibits inhibitory activity on purified HER2 kinase at much higher concentrations. Despite the minimal activity on purified protein in vitro, in vivo studies show that erlotinib inhibits the growth of HER2-driven systems effectively. Several hypotheses have been put forward to explain this discrepancy. In particular, it has been suggested that erlotinib might indirectly suppress the activity of HER2 by blocking the ability of EGFR to transactivate it when the two receptors are part of a heterodimer complex. However, an alternative possibility that has not been adequately addressed is whether the direct inhibitory action of erlotinib on the HER2 kinase might account for the observed biological responses. To distinguish between a direct effect of erlotinib on HER2 kinase in intact cells or an indirect effect of erlotinib on HER2 activity that is mediated through EGFR, we generated cell lines that express either EGFR-H2 chimeric receptor or HER2 and HER3 receptors in an EGFR-negative background. We show that dose-dependent inhibition of HER2 was achieved at the receptor level, on downstream signaling molecules, and more importantly was also translated into inhibition of cell growth. Our findings imply that the inhibitory effect of erlotinib in HER2-expressing cells may in part be mediated through direct interaction with HER2 rather than indirectly through a process that requires the presence of EGFR. [Cancer Res 2007;67(3):1228–38]

This article has been cited by other articles:

				N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone Target-based therapies in breast cancer: current status and future perspectives Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702. [Abstract] [Full Text] [PDF]

				K. P. Hoeflich, C. O'Brien, Z. Boyd, G. Cavet, S. Guerrero, K. Jung, T. Januario, H. Savage, E. Punnoose, T. Truong, et al. In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Clin. Cancer Res., July 15, 2009; 15(14): 4649 - 4664. [Abstract] [Full Text] [PDF]

				T. Araki, G. Chan, S. Newbigging, L. Morikawa, R. T. Bronson, and B. G. Neel Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation PNAS, March 24, 2009; 106(12): 4736 - 4741. [Abstract] [Full Text] [PDF]

				L. Li, H. Wang, E. S. Yang, C. L. Arteaga, and F. Xia Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells Cancer Res., November 15, 2008; 68(22): 9141 - 9146. [Abstract] [Full Text] [PDF]

				R. I. Jakacki, M. Hamilton, R. J. Gilbertson, S. M. Blaney, J. Tersak, M. D. Krailo, A. M. Ingle, S. D. Voss, J. E. Dancey, and P. C. Adamson Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study J. Clin. Oncol., October 20, 2008; 26(30): 4921 - 4927. [Abstract] [Full Text] [PDF]

				W. D. Hardie, C. Davidson, M. Ikegami, G. D. Leikauf, T. D. Le Cras, A. Prestridge, J. A. Whitsett, and T. R. Korfhagen EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-{alpha}-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1217 - L1225. [Abstract] [Full Text] [PDF]

				F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, and N. T. Ueno Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity Mol. Cancer Ther., August 1, 2007; 6(8): 2168 - 2177. [Abstract] [Full Text] [PDF]